Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, announced it has secured $65 million in Series B funding from investors including Ampersand's founder, Flagship Pioneering, Eli Lilly & Company, and several additional new investors. In addition, the company announced the advancement of two lead programs and a second discovery partnership in obesity.